Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Glioblastoma 2Hepatitis, Chronic 1Hepatitis C 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1BRCA1/2 Mutation 1

Interventions

pembrolizumab 44Gemcitabine 23enfortumab vedotin 21Nivolumab 20Cisplatin 17avelumab 16Magnetic Resonance Spectroscopy 15Carboplatin 14atezolizumab 13Specimen Handling 12Docetaxel 11sacituzumab govitecan 9Paclitaxel 8Ipilimumab 8durvalumab 6Mitomycin 5Fluorodeoxyglucose F18 5cabozantinib 4Taxes 4toripalimab 3pemigatinib 3erdafitinib 3X-Rays 3Radiosurgery 3Platinum 3Pemetrexed 3Immunoglobulin G 3CTLA-4 Antigen 3Biopsy 3ALT-803 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × rocakinogene sifuplasmid × 1 year × Clear all
NCT03502785 2025-07-10

INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma

Inovio Pharmaceuticals

Phase 1/2 Completed
35 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡